Terri-Anne Cock
Company: Amplia Therapeutics Limited
Job title: Head of Translational Biology
Seminars:
[VIRTUAL] Targeting Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases 2:30 pm
Amplia’s opportunity with AMP945 a FAK inhibitor for combination therapies Preclinical data demonstrating FAK’s role modulating the tumour and in the tumour environment Clinical evidence gathered so-far that supports progression of AMP945 combination therapy in patients with advanced pancreatic cancer Read more
day: Day Two